ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2017-11-14

Name: ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2017-11-14
Creator: ELOXX PHARMACEUTICALS, INC.

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-11-14 (fiscal Q1 2018): 27 published measures, 57 facts as tagged in accession 0001144204-17-059104.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-14
Fiscal period: fiscal Q1 2018
Accession: 0001144204-17-059104 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	6,591,027	USD
At 2017-06-30	5,845,200	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	3,276,289	USD
At 2017-06-30	4,973,994	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	3,314,738	USD
At 2017-06-30	871,206	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	957,874	USD
At 2017-06-30	33,198	USD
At 2016-09-30	287,064	USD
At 2016-06-30	810,808	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-1,266,978	USD	92
2016-07-01 to 2017-06-30	-933,577	USD	365
2016-07-01 to 2016-09-30	-933,577	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-575,324	USD	92
2016-07-01 to 2016-09-30	-573,744	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	1,500,000	USD	92
2016-07-01 to 2016-09-30	0	USD	92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	0	USD	92
2016-07-01 to 2016-09-30	50,000	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-123,205,572	USD
At 2017-06-30	-121,824,326	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	0	USD	92
2016-07-01 to 2017-06-30	-640,000	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	42,771	USD
At 2017-06-30	50,979	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	626	USD	92
2016-07-01 to 2016-09-30	8,205	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-627,449	USD	92
2016-07-01 to 2017-06-30	-2,210,532	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	1,038,456	USD
At 2017-06-30	284,421	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	1,076,289	USD
At 2017-06-30	2,773,994	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-09-30	108,569	USD
At 2017-06-30	191,597	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	135,639	USD	92
2016-07-01 to 2017-06-30	280,240	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	51,414,613	shares
At 2017-06-30	29,202,799	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	126,006,164	USD
At 2017-06-30	122,401,918	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-09-30	255,385	USD
At 2017-06-30	330,301	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2017-09-30	80,582	USD
At 2017-06-30	251,223	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-1,266,978	USD	92
2016-07-01 to 2017-06-30	-1,573,577	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-1,381,246	USD	92
2016-07-01 to 2017-06-30	-943,079	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	491,810	USD	92
2016-07-01 to 2017-06-30	480,020	USD	365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	0	USD	92
2016-07-01 to 2016-09-30	-640,000	USD	92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	1,500,000	USD	92
2016-07-01 to 2016-09-30	0	USD	92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-83,031	USD	92
2016-07-01 to 2016-09-30	54,569	USD	92

Inspect the source

Entity: ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured: 2026-09-20T05:15:09.498Z
SEC response SHA-256: b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))